Elan and Wyeth change bapineuzumab dosing over safety concern
This article was originally published in Scrip
Elan and Wyeth have discontinued the highest (2.0mg/kg) of three dosing regimens in two ongoing Phase III studies of bapineuzumab. The studies involve patients with mild to moderate Alzheimer's disease who do not carry the apolipoprotein E4 (ApoE4) allele, and the changes follow concerns about vasogenic oedema.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.